The safety profile clearly suggests that the risk of adverse events is much higher after SARS-CoV-2 infection than after receiving the BNT162b2 mRNA vaccine (Pfizer-BioNTech). The study was conducted with almost one million people. Paper publishing in NEJM.
https://www.nejm.org/doi/full/10.1056/NEJMoa2110475?query=featured_coronavirus